REGULATORS OF ANAPLASTIC LYMPHOMA KINASE AND USES THEREOF
Provided herein are ALK regulators for the treatment of diseases and disorders. For example, presented herein are ALK regulators, e.g., ALK activators, and methods of treatment and/or prevention of diseases, including neurodegenerative, neuromuscular and cognitive diseases or disorders, and methods of enhancing cognitive abilities using ALK regulators, e.g., ALK activators. Also provided herein are ALK regulators, e.g., ALK inhibitors, and methods of treatment and/or prevention of diseases such as hyperproliferative and neoplastic disorders associated with cells that express ALK, e.g., cells that exhibit increased or constitutive levels of ALK tyrosine phosphorylation using such ALK regulators, e.g., ALK inhibitors. Pharmaceutical compositions of said ALK regulators, e.g, ALK activators and inhibitors are likewise provided.
1 . A method of treating or preventing a neurodegenerative, neuromuscular or cognitive disease or disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an anaplastic lymphoma kinase (ALK) activator.
2 . (canceled)
3 . The method of claim 1 , wherein 1.0 μM of the ALK activator is capable of increasing ALK tyrosine phosphorylation above background ALK tyrosine phosphorylation in unstimulated neuroblastoma cells.
4 . The method of claim 1 , wherein the ALK activator is capable of binding to the N-terminal domain of the ALK receptor.
5 . The method of claim 1 , wherein the ALK activator is an antibody.
6 . The method of claim 1 , wherein the ALK activator is capable of binding to a heparin binding motif of the ALK receptor.
7 .- 11 . (canceled)
12 . The method of claim 1 , wherein the neurodegenerative disease or disorder is Alzheimer's disease.
13 .- 45 . (canceled)
46 . A pharmaceutical composition suitable for intraventricular administration comprising an ALK activator.
47 .- 92 . (canceled)
93 . A method of treating or preventing an ALK receptor-associated disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an ALK inhibitor, wherein the ALK inhibitor inhibits binding of heparin or a heparin/chondroitin sulfated growth factor to the ALK receptor.
94 . The method of claim 93 , wherein the ALK inhibitor inhibits binding of heparin to the N-terminal domain of the ALK receptor.
95 . The method of claim 94 , wherein the ALK inhibitor inhibits binding of heparin to the heparin binding motif of the ALK receptor.
96 .- 99 . (canceled)
100 . The method of claim 93 , wherein the ALK inhibitor binds to the ALK receptor.
101 . The method of claim 93 , wherein the ALK inhibitor is an antibody that specifically binds the ALK receptor.
102 . The method of claim 93 , wherein the ALK inhibitor is a soluble protein comprising a heparin-binding motif.
103 . The method of claim 102 , wherein the soluble protein comprises a heparin-binding portion of an ALK N-terminal domain.
104 .- 105 . (canceled)
106 . The method of claim 93 , wherein the ALK receptor-associated disorder is a hyperproliferative disorder.
107 . The method of claim 106 , wherein the hyperproliferative disorder is cancer.
108 . The method of claim 107 , wherein the cancer is a lymphoma.
109 . The method of claim 108 , wherein the lymphoma is an anaplastic large-cell lymphoma.
110 . The method of claim 107 , wherein the cancer is a non-small cell lung cancer, inflammatory breast cancer, medulloblastoma, rhabdomyosarcoma, colorectal cancer, pancreatic cancer, myofibroblastic tumors, Ewing's sarcomas, head-and-neck cancer, neurofibromatosis, ovarian cancer, or glioblastoma.
111 . The method of claim 107 , wherein the cancer is a neuroblastoma.
112 .- 132 . (canceled)